As we enter February 2024, the Hong Kong market has shown resilience, with investors navigating through economic headwinds and finding pockets of growth amidst global uncertainty.
At least five subsidiaries affiliated with the Guangzhou Pharmaceutical Holdings Limited, a company to enter the Fortune Global 500 with traditional Chinese medicine as its major business, will go public listings within the five years, according to a senior company officer.